{\rtf1\ansi\ansicpg1252\cocoartf949\cocoasubrtf430
{\fonttbl\f0\froman\fcharset0 TimesNewRomanPSMT;\f1\fswiss\fcharset0 ArialMT;}
{\margl1800\margr1600\margt500\margbl1440}
{\pard\sa900\fs50\f0\i Media Release\par}
{\pard\f0\li0\ri0\sa360\sl360\fs22 Basel, 30 September 2003 \line \line {\b Roche and 
Protein Design Labs restructure commercial alliance on Zenapax} \line PDL obtains world-wide 
rights - Roche to continue Zenapax in transplant indication\par}{\pard\f0\li0\ri0\sa360\sl360\fs22 Protein Design 
Labs, Inc. (PDL) and Roche announced today that PDL has obtained exclusive worldwide rights to market, 
develop and sell Zenapax (daclizumab) in all disease indications other than organ transplantation. Roche 
will continue to market Zenapax in transplantation indications until 2007. \par}{\pard\f0\li0\ri0\sa360\sl360\fs22 The 
PDL-Roche collaboration dates back to 1989, when Roche acquired the rights to commercialize Zenapax 
worldwide. Since then the product has become an important medicine within Roche\u8217?s transplantation portfolio. 
Roche and PDL now agreed to restructure the alliance on Zenapax in order for PDL to develop Zenapax 
in therapeutic areas other than those where Roche has a strong presence. Roche continues to be committed 
to the transplantation area with CellCept, the cornerstone of potent, low-toxicity immunosuppressive 
regimens, and Valcyte, Roche\u8217?s new oral antiviral for the treatment of Cytomegalovirus. \par}{\pard\f0\li0\ri0\sa360\sl360\fs22 {\b About 
the agreement} \line PDL will pay Roche 80 million dollars upon signature of the agreement. 
Under the agreement, PDL will immediately assume worldwide responsibility for the development and, if 
successful, sales and marketing of Zenapax in all indications other than transplantation. PDL will pay 
Roche an additional sum if PDL decides to acquire Zenapax in the transplantation indication.\par}{\pard\f0\li0\ri0\sa360\sl360\fs22 \u8220?With 
this agreement Zenapax will potentially benefit a broader patient population. We are proud to help enable 
our long time partner to achieve one of its key corporate goals with this new arrangement. Zenapax has 
been and continues to be an important medicine. Roche is committed to developing new immunosuppressive 
treatments which should enhance a higher quality of life of transplant recipients.\u8221? said William M. 
Burns, Head of Roche\u8217?s Pharmaceuticals Division. \line Mark McDade, Chief Executive Officer, 
PDL, said, "As the first antibody we humanized, we are deeply committed to the broadest possible 
development of Zenapax in important diseases outside of transplantation. This agreement creates a means 
to continue Roche\u8217?s commitment to the transplant community, at the same time providing a clearer path 
for PDL to expand uses of daclizumab in underserved medical markets, such as ulcerative colitis and 
multiple sclerosis. We are indebted to Roche\u8217?s significant efforts during the past five years aimed 
at establishing Zenapax as a key element in renal transplantation. Under Roche\u8217?s development, Zenapax 
has demonstrated immunosuppressive activity and an excellent safety profile in more than 20,000 patients 
treated in the United States, Europe and Asia. \par}{\pard\f0\li0\ri0\sa360\sl360\fs22 "PDL may now fully exploit 
the opportunity in inflammatory bowel disease, a core therapeutic focus for us, and retain the full 
financial benefits of that opportunity with little or no obligation to Roche in the future," Mr. 
McDade added. "We gain additional flexibility to explore significant partnerships in larger disease 
indications and are positioned to generate PDL product revenues by 2007, given the option to begin marketing 
Zenapax directly via a PDL sales and marketing effort. We are very excited at the opportunities for 
Zenapax as a PDL marketed product.\u8221?\par}{\pard\f0\li0\ri0\sa360\sl360\fs22 {\b Roche in transplantation 
} \line Roche is strongly committed to improving the long-term outcomes of transplantation 
and enhancing the quality of life of transplant recipients. Roche has developed innovative therapies 
that improve graft and post-transplant health: CellCept is the cornerstone of low toxicity immunosuppressant 
therapies. CellCept is the largest selling branded immunosuppressive in North America, offers both physicians 
and patients the possibility of an effective long term immunosuppressive regimen with low toxicity, 
Zenapax prevents the acute rejection of the newly transplanted organ, and Valcyte developed for the 
prevention of cytomegalovirus, a dangerous viral infection associated with transplantation. With Isotechnika, 
Roche is also co-developing ISA247, a potentially more potent and less toxic calcineurin inhibitor. 
In addition, Roche supports basic research in transplantation with its funding of the independent Roche 
Organ Transplantation Research Fund (ROTRF), which directly supports innovative research projects attracting 
new researchers with innovative and novel scientific ideas to meet unmet medical needs in solid organ 
transplantation.\line \line {\b Roche Business Development and Alliance 
Strategy} \line Roche is a distinctive alliance partner with expertise in identifying 
cutting-edge innovation that can lead to new and improved medicines. Over the past 18 months alone, 
Roche has formed 40 new partnerships, which span a wide range of therapeutic areas and technologies, 
making it an industry leader. Through its alliance strategy, Roche creates value with its partners by 
transforming those business transactions into productive relationships. A key element of this strategy 
is to enable its partners to achieve their vision while maintaining their cultural identity and entrepreneurial 
spirit.\par}{\pard\f0\li0\ri0\sa360\sl360\fs22 {\b About Roche} \line Headquartered in Basel, 
Switzerland, Roche is one of the world\u8217?s leading innovation-driven healthcare groups. Its core businesses 
are pharmaceuticals and diagnostics. Roche is number one in the global diagnostics market, the leading 
supplier of pharmaceuticals for cancer and a leader in virology and transplantation. As a supplier of 
products and services for the prevention, diagnosis and treatment of disease, the Group contributes 
on a broad range of fronts to improving people\u8217?s health and quality of life. Roche employs roughly 65,000 
people in 150 countries. The Group has alliances and R&D agreements with numerous partners, including 
majority ownership interests in Genentech and Chugai. \par}{\pard\f0\li0\ri0\sa360\sl360\fs22 {\b About 
PDL} \line Protein Design Labs is a leader in the development of humanized antibodies 
to prevent or treat various disease conditions. PDL currently has antibodies under development for autoimmune 
and inflammatory conditions, asthma and cancer. PDL holds fundamental patents for its antibody humanization 
technology. Further information on PDL is available on the Internet (http://www.pdl.com).\par}{\pard\f0\li0\ri0\sa360\sl360\fs22 All 
trademarks used or mentioned in this release are legally protected.\par}
{\pard \par}
{\pard\sb180\f1\fs22 {\b F. Hoffmann-La Roche Ltd}\line 4070 Basel\line Switzerland \par}
{\pard\sb180\f1\fs22 Corporate Communications\line Roche Group Media Relations \par}
{\pard\sb180\f1\fs22 Tel. +41 61 688 88 88\line Fax +41 61 688 27 75\line www.roche.com \par}
}